3.5% Below Target

The consensus price target for GSK is $52.45, close to the current price of $50.67 (3.5% implied move). Based on 29 analyst estimates, the stock appears fairly valued near current levels.

GSK has a consensus rating of "Hold" based on 29 Wall Street analysts. The rating breakdown is mixed, with 16 Hold ratings making up the largest segment. The consensus 12-month price target of $52.45 implies 3.5% upside from current levels.

With a forward P/E of 13.9826x, GSK trades at a relatively low valuation. The consensus target of $52.45 implies 3.5% appreciation, suggesting the market may be pricing in risks.

The most bullish Wall Street analyst has a price target of $85 for GSK, while the most conservative target is $35.25. The consensus of $52.45 represents the median expectation. Our quantitative valuation model projects a bull case target of $46 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.

GSK is heavily covered by Wall Street, with 29 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 9 have Buy ratings, 16 recommend Hold, and 4 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.

The 12-month GSK stock forecast based on 29 Wall Street analysts shows a consensus price target of $52.45, with estimates ranging from $35.25 (bear case) to $85 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $35, with bear/bull scenarios of $22/$46.

Our quantitative valuation model calculates GSK's fair value at $35 (base case), with a bear case of $22 and bull case of $46. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 50/100.

GSK trades at a forward P/E ratio of 14.0x based on next-twelve-months earnings estimates compared to a trailing P/E of 6.9x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.

GSK appears fairly valued according to analysts, with a "Hold" rating and minimal upside to the $52.45 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.

GSK analyst price targets range from $35.25 to $85, a 95% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $52.45 consensus represents the middle ground. Our model's $22-$46 range provides an independent fundamental perspective.